辞职消息公布前，博雅生物公布了2025年业绩预亏的公告。预计2025年归母净利润仅为1.05亿元—1.37 亿元，同比下滑65.62%-73.55%，扣非净利润预计亏损750万元—1500万元，而2024年同期盈利3.02亿 元。 值得注意的是，这不是该公司第一次出现高管辞职现象。在2021年华润医药斥资48亿元控股博雅生物， 并成功入局血液制品行业后，该公司的管理层波动、业绩震荡以及战略整合问题不断。 博雅生物的频繁人事更迭，让华润也着急了！ 2月27日，博雅生物（300294.SZ）发布公告称，公司董事会于2月26日收到董事、总裁任辉递交的书面 《辞任报告》，因工作变动原因，任辉申请辞去第八届董事会董事、战略与ESG委员会委员、总裁及法 定代表人四项职务，辞任后不再担任公司任何职务。 任期最短总裁出现 2024年12月起，任辉担任博雅生物非独立董事，2025年5月由副总裁升任总裁、法定代表人，任辉原定 任期至2027年3月20日。为什么仅履职约10个月就要辞职？ 2024年11月，博雅生物以18.2亿元收购绿十字香港控股有限公司，旨在获取其血液制品牌照和4家在营 浆站资源。然而，其全资子公司安徽格林克医药 ...

保障战略资源安全，挺进产业升级前沿，是经济大省必须扛起的责任。在关系国计民生的生物医药领 域，山东如何"挑大梁"？答案，或许就铭刻在一支支小小的药瓶上。 血液制品，是国家重要的战略储备资源，在临床救治中发挥着不可替代的关键作用，无论是应对突发公 共卫生事件、抢救危重患者，还是在疫情防控等关键时期，它都是保障生命安全的重要支撑。它的供给 安全与技术创新，直接关乎重大疾病救治、公共卫生应急与国家安全体系。山东泰邦生物制品有限公司 二十余年如一日，将"为人类健康造好药"的使命，锻造成了一把破解资源瓶颈、攻坚核心技术的"硬 核"钥匙。作为国家定点、山东省唯一的集科研、生产、经营于一体的血液制品专业化企业，它不仅是 产业创新的样本，更是观察山东以新质生产力重塑传统优势产业、在高质量发展中"走在前、开新局"的 生动切片。 始于国需，成于"至信"：一根融入文化基因的质量脊梁 通讯员席智赢 拓展纵深，筑牢根基：一张覆盖全国的产业与责任网络 企业的竞争力，源于全产业链的深度掌控与市场格局的广度开拓。 在前端，泰邦生物在山东、河北两省依法设立16家单采血浆站，全部实现智能化、规范化管理，从源头 夯实了战略资源的供给基础。 泰邦生 ...

Core Viewpoint - Haier Group's ecological layout is facing a significant test as its industrial internet subsidiary, Kaos, has submitted an IPO application to the Hong Kong Stock Exchange, marking a critical moment for the company's strategic transformation and its leadership transition [2][3]. Group 1: Haier's Strategic Moves - Haier has aggressively pursued capital market ambitions, acquiring major stakes in companies like Shanghai Laishi and Auto Home, and currently holds interests in eight listed companies, forming a robust "ecological empire" [3]. - The complexity of Haier's diversified ecosystem raises questions about the actual market competitiveness of its subsidiaries versus their reliance on the group's support [4]. Group 2: Kaos's Business Model and Performance - Kaos offers a combination of digital operating systems, AI, and IoT devices, serving over 160,000 enterprises, with a market share of 1.2% in China's industrial data intelligence solutions market [5]. - Despite generating approximately 5 billion in revenue from 2023 to 2025, Kaos has struggled with profitability, reporting a net loss of 82.72 million in 2023 and a net profit margin of only 1.3% in 2024 [6][7]. - The company's low gross margin, hovering around 17.8% to 18%, is attributed to an imbalanced business structure, with the more profitable data intelligence solutions accounting for only 18.3% of revenue in 2023 [8][9]. Group 3: Revenue Dependency and Risks - A significant portion of Kaos's revenue comes from related party transactions, with over 80% of its income derived from its top five clients, primarily Haier itself, raising concerns about its independence and sustainability [10]. - The performance of Kaos in the capital market will largely depend on Haier's core business, which remains focused on home appliances [11]. Group 4: Haier's Core Business Challenges - Haier's home appliance segment, particularly its traditional products, is showing signs of fatigue, with growth rates lagging behind the overall market [12][15]. - In the first three quarters of 2025, Haier's revenue reached 234.05 billion, with a net profit of 17.37 billion, but its net profit margin of 7.4% is the lowest among its major competitors [18][20]. Group 5: Financial Health and Management Issues - Haier's high sales expense ratio of 10.6% compared to its competitors indicates potential inefficiencies in cost management [20]. - The increase in accounts receivable turnover days suggests that Haier may be extending credit terms to maintain revenue growth, which could pose risks in cash flow management [22]. Group 6: Diversification and Future Outlook - Haier's aggressive diversification strategy has led to significant goodwill on its balance sheet, with goodwill amounting to 27.6 billion, raising concerns about potential impairments if acquisitions do not meet performance expectations [25][26]. - The company's recent regulatory issues in its financial services division highlight the reputational risks associated with its rapid expansion [27][28]. - As Haier pushes for more assets to be listed in the capital market, the sustainability of its ecological narrative and the profitability of its subsidiaries remain in question [29][32].

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has announced its profit distribution plan for the first three quarters of 2025, which includes a cash dividend of 0.153 RMB per 10 shares for all shareholders, excluding shares held in the company's repurchase account [2][3][7]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the third extraordinary general meeting of shareholders held on December 15, 2025 [3][5]. - The cash dividend will be distributed based on the total share capital excluding the 69,081,952 shares held in the repurchase account, resulting in a total of 6,568,902,885 shares eligible for the dividend [2][7]. - The total cash dividend amount is calculated to be 100,504,214.14 RMB, with an adjusted per-share dividend of 0.0151407 RMB [2][11]. Group 2: Dividend Payment Details - The record date for the dividend distribution is set for February 9, 2026, and the ex-dividend date is February 10, 2026 [7][8]. - Cash dividends will be directly credited to shareholders' accounts through their securities companies on the ex-dividend date [9]. - The company will not issue bonus shares or convert reserves into share capital as part of this distribution [4][5]. Group 3: Tax Implications - Different tax rates will apply to various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors holding different types of shares [7]. - The tax implications for individual shareholders will depend on their holding period, with specific amounts to be paid based on the duration of their shareholding [7].

Core Viewpoint - The company, Boya Biological, emphasizes its position as a cash-intensive blood product manufacturer with a long production cycle, highlighting the importance of inventory management strategies in response to various influencing factors [1] Group 1: Company Operations - The company acknowledges that inventory turnover is affected by multiple factors including industry characteristics, market supply and demand, and regulatory policies [1] - The company plans to align its product production schedule with its raw plasma supply scale to ensure adequate market supply and maintain reasonable inventory levels [1] Group 2: Inventory Management Strategy - The company intends to develop a comprehensive inventory management strategy that considers the aforementioned factors to optimize its operations [1]

Group 1 - The company, Boya Bio-Pharmaceutical, is characterized as a blood product enterprise with high cash payment requirements and long production cycles [1] - The company plans to strictly regulate its product production schedule based on its raw plasma scale to ensure market supply and maintain reasonable inventory levels [1]

Group 1 - The core viewpoint of the news is that He Yuan Bio has shown a significant increase in stock price and trading activity, indicating positive market sentiment towards the company [1] - As of January 13, He Yuan Bio's stock price rose by 2.03% to 79.57 CNY per share, with a total market capitalization of 28.446 billion CNY [1] - The company has experienced a year-to-date stock price increase of 15.14%, with a 10.09% rise over the last five trading days and a 2.62% increase over the last 20 days [1] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [1] - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, a significant increase of 84,075% compared to the previous period [2] - For the period from January to September 2025, He Yuan Bio reported operating revenue of 19.6608 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to shareholders of -121 million CNY, also a decrease of 8.44% year-on-year [2]

Economic Development - The GDP of Huaxi District is projected to rise from 63.7 billion yuan in 2020 to 98 billion yuan in 2024, with a historic breakthrough of 100 billion yuan expected in 2025, marking a significant milestone as the fourth in the province and third in the city to achieve this level [2] - Huaxi District has been recognized for four consecutive years among the top 100 districts in comprehensive competitiveness in Western China and has been included in the top 100 districts for tourism strength nationwide for six years [2] Industrial Growth - The Huaxi District emphasizes industrial development, with significant projects such as the surface treatment industry base and the establishment of a blood products production base with a total investment of 1.2 billion yuan [3] - The digital agriculture sector is advancing, with the establishment of a digital mushroom production base that utilizes technology to enhance production efficiency [3] - The agricultural sector has seen improvements, with the total output value of agriculture, forestry, animal husbandry, and fishery maintaining a leading growth rate in the city [3] Tourism and Culture - The tourism industry in Huaxi District has achieved notable success, with several establishments receiving high ratings, including a five-star hotel and a national-level homestay [4] Urban and Rural Integration - Huaxi District has made strides in urban renewal, improving living conditions for residents by renovating old neighborhoods and increasing public amenities [6][7] - The district has implemented comprehensive rural governance, achieving a 99.8% rate of centralized water supply in rural areas and 100% coverage of public sanitation facilities [6] Social Welfare and Quality of Life - The district has focused on enhancing the quality of life for residents, with initiatives such as opening the Huaxi Lake Park and improving public services in the administrative center [9][10] - Employment opportunities have increased, with 75,000 new urban jobs created and a steady rise in per capita disposable income for both urban and rural residents [10] Environmental Sustainability - Huaxi District has prioritized ecological protection, achieving a stable air quality rate of over 98% and maintaining high standards in environmental monitoring [10][11] - The district has engaged in green development initiatives, with over 50% of the regional GDP coming from the green economy [11]

Core Viewpoint - The company, Shanghai Laishi, emphasizes its focus on producing and selling blood products while adhering to national regulations and procurement management standards [1]. Group 1: Company Operations - Shanghai Laishi's main business involves the production and sale of blood products, ensuring compliance with national drug management regulations [1]. - The company supplies products that meet national standards to various domestic medical institutions to fulfill clinical emergency and routine medical needs [1]. Group 2: Procurement and Disclosure - The company stated that any significant procurement cooperation will be disclosed in accordance with regulatory requirements and information disclosure rules [1].

Group 1: Industry Outlook - The blood products industry is expected to experience significant growth due to factors such as economic development, aging population, and increased clinical demand for blood products [1] - In 2023 and 2024, the industry is projected to see a supply-demand mismatch, with a 5% increase in plasma collection expected in the first half of 2025 [2] Group 2: Company Performance and Projections - The company anticipates a cash dividend of approximately CNY 256 million for 2024, representing 41.79% of the net profit attributable to shareholders for 2023 [5] - For 2025, the expected cash dividend remains at CNY 256 million, accounting for 34.33% of the net profit for 2024 [6] - In the first three quarters of 2025, the company's revenue and net profit attributable to shareholders decreased due to capacity expansion efforts [7] Group 3: Production and Capacity - The company expects to collect nearly 1,600 tons of plasma in 2025, with a projected output of over 1,400 tons [8] - The total production capacity has been expanded to over 3,000 tons following the completion of capacity upgrades in 2025 [7] Group 4: Research and Development - The company is advancing the development of the fourth generation of immunoglobulin, with expected regulatory approval for new indications by 2027 [9][10] - The company is also focusing on the development of human coagulation factors, with anticipated approvals for new products in 2027 [10] Group 5: Market Expansion and Control Transfer - The company is actively pursuing overseas market opportunities, with plans for regulatory registration and export sales [3] - The transfer of control to China National Biological is in progress, with significant steps taken towards finalizing the transaction by June 30, 2026 [4][12] Group 6: Infrastructure and Product Range - The company operates a total of 38 plasma collection stations, ranking third in the industry [11] - The product range includes 11 varieties across multiple specifications, also placing the company third in the industry [11]